AstraZeneca shares suffered their biggest fall in 15 months on Thursday after the UK’s largest drugmaker said a heart ...

Astrazeneca (AZN) closed at $164.52 in the latest trading session, marking a -2.59% move from the prior day. This change lagged the S&P 500's 0.19% loss on the day. Elsewhere, the Dow lost 0.59%, ...

Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more ...

The drug for a rare type of heart disease failed to meet the primary target of a late-stage clinical trial, denting hopes for ...

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...